back to overview

news

MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

December 07, 2021 + Jessica Di Palo
3 Min read

‘Dark green’ fund aims to help healthtech innovators to become global leaders

MTIP, the Swiss healthtech focused private equity firm, has today announced the closing of its MTIP Fund II, SCSp (“The fund”) at USD $250 million in capital commitments. The oversubscribed fund, which closed above its target of $225 million, continues its predecessor fund’s strategy of investing in growing and innovative healthtech companies primarily across Europe.

The fund, which is one of the few healthtech-specific private equity funds focused on Europe, provides growth capital to entrepreneurial and fast-growing digital health and digitally-connected medical device companies. MTIP Fund II is a designated ‘dark green’ fund, under Article 9 of the EU’s Sustainable Finance Disclosure Regulation, meaning its objective is to target sustainable investments.

MTIP Fund II seeks to capitalise on Europe’s rapidly expanding healthtech landscape, providing up to €25 million in funding to help promising scale-up companies become global leaders. After a strong first closing in late March of this year, MTIP has completed the final closing of its second fund above its original target with capital raised from new and existing investors, including multiple renowned institutional investors, pension funds, family offices, hospitals, and foundations.

MTIP celebrates final closing of its second healthtech fund

“We are excited to announce the successful closing of our second fund and continue our mission to build the healthtech leaders of tomorrow,” said Dr. Christoph Kausch, Managing Partner at MTIP. “The trust our investors have put in us is a great endorsement of our strategy that’s built on our singular focus and proven approach to value creation.”

Dr. Andreas Schönenberger, CEO at the Swiss health insurance company Sanitas, is one of the investors in MTIP Fund II. He commented: “MTIP has unique expertise in healthtech and fosters innovation in this under-served private equity sector. Our collaboration with MTIP gives us access to innovative healthtech solutions that enable us to generate added value for our customers.”

The worldwide COVID-19 pandemic has accelerated innovation in the healthcare sector and led to the adoption of new technologies. MTIP’s investment team closely observes relevant healthcare and societal trends to source the most significant players in various markets. MTIP streamlines an exclusive flow of investment opportunities, which is enhanced by the firm’s network, its leading role in Europe, as well as its specific strategy to invest solely in healthtech companies. The company has already made five investments out of its second fund: Oviva, Trialbee, Koa Health, Intelligencia, and Mediktor.

 

ABOUT MTIP

MTIP is a fast-growing pan-European healthtech growth capital investor, based in Basel, Switzerland. We invest in digital health and digitally connected medical device companies, with offerings that provide clear health-related economic benefits. Our entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with our portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors.

Share the Article

news

MTIP leads the €20 million growth financing round in LynxCare

Largest capital round ever in digital health in Belgium

blog

Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development

blog

The psychology of decision making

What makes a good investor?

blog

Revolutionizing medical triage with artificial intelligence

Mediktor's solution for medical triage

news

MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

MTIP Fund II is closed!

blog

Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!

news

MTIP invests in Mediktor

New investment in Mediktor

blog

SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right

news

MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round

news

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia

blog

Private Equity 101: Part one – Glossary

Are you new to the healthtech space?

blog

Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey

blog

Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations

news

MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II

blog

How to pitch to a healthtech Investor

Blog Pitching

news

MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health

news

MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020

press

4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour

news

MTIP invests in Trialbee

New investment in Trialbee

news

TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round

news

The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April

news

MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020

news

New MTIP investment in Oviva

New investment in Oviva